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ABSTRACT 
 
BACKGROUND AND OBJECTIVES: 
Endotracheal intubation is required for giving general anaesthesia for 
which adequate muscle relaxation is necessary. Suxamethonium is still used 
as a relaxant for endotracheal intubation . Rocuronium ,a non depolarising 
muscle relaxant was compared here for tracheal intubating conditions. 
METHODS: 
100 patients of ASA I and II were divided randomly into 2 groups 
undergoing elective surgeries: 
Group I - Suxamethonium 
Group II - Rocuronium. 
RESULTS AND INTERPRETATIONS: 
The intubating conditions were excellent in group I Suxamethonium as 
against Group II  Rocuronium in 60 secs. 
CONCLUSION: 
Rocuronium can be used as alternative when suxamethonium is 
contraindicated for rapid intubation but not if anticipated difficult airway is 
present. 
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INTRODUCTION 
Endotracheal intubation is necessary for giving general anaesthesia. 
It is important for anaesthesiologist to reduce the airway injuries 
associated with tracheal intubation. Good  intubating conditions are produced 
by adequate depth of anaesthesia and muscle relaxation. 
 Suxamethonium is often used in surgeries as it provides excellent 
intubating conditions and early establishment of patent airway thereby 
reducing airway injuries and aspiration. Still the side effects it may produce 
may range from post operative myalgia to life threatening complications like 
dysrhythmias, hyperkalemia, malignant hyperthermia. 
To give good intubating conditions and early establishment of airway 
patency in patients with risk of complications with Suxamethonium, 
Rocuronium a newer steroidal non depolarising muscle relaxant was 
introduced which has rapid onset of action comparable to Suxamethonium. 
This study compares the intubating conditions achieved with 
Suxamethonium and Rocuronium. 
 
  
 
 
 
OBJECTIVES 
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OBJECTIVES 
 This study is to compare the intubating conditions achieved in patients 
undergoing elective surgeries under General Anaesthesia with 
Suxamethonium or Rocuronium in 60 secs and complications in both groups. 
 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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HISTORY 
The arrow poison used for hunting by the native people of South 
America has been known for centuries. Shortly after the first Spaniards 
arrived in the New World in the sixteenth century accounts of the mysterious 
poison began to appear. Among the more spectacular personalities reporting 
on the poison was Sir Walther Raleigh (1552-1618), he described the 
poison in 1596, and it was one of his captains who named the poison 
"Ourari". Among others, the French scientist Charles-Marie de la 
Condamine (1701-1774) and the English scientist Edward Bancroft (1744-
1821) brought back to Europe samples of the curare poison. For many years 
these samples were the basis for experiments in different parts of Europe. 
Benjamin Brodie (1783-1862) and his assistant Edward Nathaniel 
Bancroft (1772-1842; son of Edward Bancroft), showed that the poison 
paralysed the respiratory muscles, and that an animal given curare could be 
kept alive if ventilated. In 1856, Claude Bernard (1818-1878) published his 
classic experiments on frogs, and he found that curare acted peripherally, 
causing paralysis of the muscle by its effect at the Acetylcholine receptor site 
in NMJ. In the 1930s H.H.Daie, W. Felberg and M. Vogt proved that 
Acetylcholine, the chemical neurotransmitter of the NMJ acted on skeletal 
muscle.  Since then the NMJ has been the most studied junction in the body. 
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The basic concept of Acetylcholine as the chemical transmitter, being 
synthesized in the nerve endings and acting on postsynaptic receptors, has not 
been changed over the years. However, in recent years important advances in 
modern technology, not least in electron microscopy, electrophysiology, 
immunology and DNA technology, have much increased our knowledge of 
the transmission process. 
In 1942 Griffith and Johnson reported that D-Tubocurarine is a safe 
drug to use during surgery with good muscle relaxation. Later, Cullen 
reported that D-Tubocurarine had been given to 131 patients under general 
anaesthesia to produce additional skeletal muscle relaxation greater than that 
provided by the Volatile anaesthetic agents alone. 
During subsequent years, as the clinical pharmacology of the 
neuromuscular blocking drug has been refined, and as the drugs themselves 
have been improved, the use of muscle relaxant has become a vitally 
important aspect of modern anaesthesiology practice. The development of 
new synthetic relaxants had greatly increased the clinicians options for 
providing skeletal muscle relaxation. 
Suxamethonium, introduced by Thesleff and Foldes et al in 1952, 
revolutionized anaesthetic practice by providing intense neuromuscular 
blockade of very rapid onset and ultra short duration, thereby greatly easing 
the maneuver of tracheal intubation, 
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The synthetic and semisynthetic nondepolarizing drugs, such as 
Gallamine, Dimethyl tubocurarin, and Alcuronium, introduced over the next 
decade, were alternative to D-Tubocurarine. They were not considered as 
replacements for D-Tubocurarine because they all produced cardiovascular 
side effects, showed long duration of action similar to that of                                   
D-Tubocurarine. 
Baird and Reid in 1967 reported on the clinical administration of the 
aminosteroid Pancuronium. 
In the early 1980s two more newer muscle relaxants of intermediate 
duration of action namely Atracurium and Vecuronium was introduced into 
the clinical practice. These drugs revolutionized the performance of 
balanced general anaesthesia by providing very good muscle relaxation of 
faster onset and at the same time more rapid measurable faster recovery, 
without depending on kidneys solely for their metabolism.  
Their faster onset and shorter duration of action property is more 
comparable with Suxamethonium which encouraged tracheal intubation for 
the use of non depolarising relaxants. 
At the same time the property of faster measurable recovery and 
complete antagonism of the residual blockade by Anticholinesterases made 
it convenient to provide paralysis by continuous infusion of these non 
depolarising relaxants. 
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Along with introduction of Pipecuronium, Doxacurium, Mivacurium 
and Cisatracurium, the early 1990 witnessed the introduction of a steriodal 
compound “Rocuronium” of intermediate duration, with an onset of action 
that is faster than that of vecuronium. 
Rocuronium is the first non-depolarizer considered to be an acceptable 
substitute for Suxamethonium in facilitating rapid intubation of the trachea. 
Rocuronium is a step forward in the development of improved 
neuromuscular blocking agents and is indeed a new milestone in the clinical 
practice of anaesthesioiogy. 
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REVIEW OF LITERATURE 
Puhringer F.K.etal., (1992)35 conducted a study to assess the 
intubating conditions achieved with Suxamethonium and Rocuronium under 
iv anaesthesia with propofol, alfentanil and Nitrous oxide in 100 patients. 
The neuromuscular effects of both drugs were quantified by recording the 
indirectly evoked twitch response of adductor pollicis muscle after ulnar 
nerve stimulation. Patients were given either 0.6 mg/kg Rocuronium or 1 
mg/kg Suxamethonium intravenously. Sixty seconds after the administration 
of the muscle relaxant, the trachea was intubated and the intubating 
conditions were scored by a "blinded" assessor. Intubating conditions were 
not different between Rocuronium and Suxamethonium groups. They 
concluded that in spite of the pharmacodynamic differences between 
sucamethonium and Rocuronium, the intubating conditions after 
administration of both compounds are similar and developed at the same rate. 
Cooper R. et al., (1992)8 conducted the study assessing intubating 
conditions after administration of Org 9426 (Rocuronium) 600 ug/kg at 60 or 
90s in groups of 20 patients anaesthetized with Thiopentone, Nitrous oxide in 
Oxygen and small doses of Fentanyl, and compared the data with those 
obtained after Suxamethonium 1 mg/kg in similar groups of patients. 
Intubating conditions after Org 9426 were found to be clinically acceptable 
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(good or excellent) in 95% of patients at 60s and in all patients at 90s and in 
all patients at both times after Suxamethonium. 
Huizinga A.C. et al., (1992)18 investigated the intubating conditions 
and neuromuscular blocking profile following 600 ug/kg Rocuronium. They 
were compared with conditions following 1.5 mg/kg Suxamethonium.   
Rocuronium produced good to excellent intubating conditions at 60 as well 
as 90 seconds after administration, even though there was only a partial 
blockade of adductor pollicis muscle. Intubating conditions following 
Suxamethonium were comparable with those after Rocuronium. Rocuronium 
may have a major advantage over existing non-depolarizing muscle relaxants 
due to the early presence of excellent intubating conditions. 
Porte F. et al (1993)14 studied the dose response relationship on 
diaphragm and adductor pollicis using Rocuronium. They concluded that the 
dose necessary to block the diaphragm is 1.5 to 2 times higher than that for 
the adductor pollicis. A dose of at least 0.5 mg/kg could be necessary to 
produce good intubating condition because such a dose is necessary to block 
the diaphragm. 
Wicks T.C. (1994)46 Rocuronium is a new non-depolarising 
neuromuscular blocking drug. Its onset of action is comparable to that of 
Suxamethonium, with good to excellent intubating conditions possible 1 
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minute after doses two times the ED95 (600 ug/kg). The ED95 of 
Rocuronium is essentially the same for children as for adults, Rocuronium is 
readily reversed with conventional doses of cholinesterase inhibiting drugs. 
A new agent, Rocuronium possesses a very stable cardiovascular profile and 
a rapid onset of action. It may be useful for rapid sequence intubation without 
unacceptable delays in the spontaneous recovery of neuromuscular function. 
Feldman S.A. (1994)15 studied the onset time and intubating 
conditions of Rocuronium. The rapidity of onset of Rocuronium in man 
appears to be due to an early presynaptic effect. Observations, which are 
difficult to explain, are that increasing the dose above about 2 x ED90 does 
not shorten the time of onset and 'priming' also has no beneficial effect.   
Although some studies have produced evidence that Rocuronium can 
produce smooth easy intubating conditions in 60s, 90s would appear to be 
close to the time when excellent conditions can be guaranteed. 
Nilesh Kumar Patel et al., (1995)33 compared Rocuronium Vs 
Suxamethonium for emergency surgery and rapid sequence intubation. There 
study suggests that 1) Rocuronium, 0.9 mg/kg provides comparable tracheal 
intubating conditions as Suxamethonium 1.5 mg/kg; 2) Suxamethonium, 1.5 
mg/kg has a more rapid onset of complete block at the orbicularis occuli than 
does Rocuronium ; and 3) visual loss of TOF may not always be necessary to 
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ensure good- excellent tracheal intubating conditions. 
The study comparing the intubating conditions as well as onset and 
clinical duration of  0.6 mg/kg (2 x ED95) with 1 mg/kg Suxamethonium (3 x 
ED95) by .Latorre F. et al,, (1996)24 showed results the that intubating 
conditions assessed were clinically acceptable(excellent or good) after 
Rocuronium and Suxamethonium. They concluded that Rocuronium has an 
onset time of about 3 minutes and a clinical duration of relaxation of nearly 
half an hour. These data are supported by various studies, while others show 
shorter times, probably due to different monitoring techniques. In spite of the 
pharmacodynamic differences between Rocuronium and Suxamethonium, the 
intubating conditions after administration of both compounds are comparable 
and develop at the same rate. 
 In elective cases with Rocuronium and Suxamethonium as RSI 
inducing with Thiopentone Sparr H.J. et al., (1996)40 assessed the intubating 
conditions. They concluded that Rocuronium is a suitable alternative to 
Suxamethonium for rapid tracheal intubation even under unsupplemented 
Thiopentone anaesthesia, at least in elective, otherwise healthy patients. Its 
use for rapid sequence induction under emergency conditions, however, 
needs further investigation. 
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Tang J., Joshi G.P. and White P.F. (1996)43 studied tracheal 
intubating conditions and neuromuscular effects of Suxamethonium, 
Rocuronium and mivacurium. They concluded that Rocuronium appears to be 
an acceptable alternative to Suxamethonium for tracheal intubation. 
However, longer duration of action of Rocuronium increases the need for 
reversal drugs. 
Rocuronium pretreatment at 3 and 1.5 minutes before Suxamethonium 
administration on fasciculations by Motamed C, Choquette R., and Donati 
F (1997)31 to assess the effect of Rocuronium. They concluded that the 
incidence and severity of Suxamethonium fasciculations can be reduced by 
giving 0.05 mg/kg Rocuronium either 1.5 minute or 3 minutes before 
Suxamethonium. The effects of 2 mg/kg Suxamethonium with Rocuronium 
pretreatment, and 1 mg/kg Suxamethonium, without pretreatment are similar 
with respect to intubating conditions, onset of paralysis and duration of 
blockade. 
Rapid sequence induction of anaesthesia using Rocuronium 0.6 or 1.0 
mg/kg or Suxamethonium 1.0 mg/kg as the neuromuscular blocking drugs by 
McCourt K.C. et al., (1998)27 for tracheal intubating conditions showed the 
results that the intubating conditions to be significantly superior with the 1.0 
mg/kg dose of Rocuronium. It is concluded that Rocuronium 1.0 mg/kg can 
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be used as an alternative to Suxamethonium l.0mg/kg as part of a rapid 
sequence induction provided there is no anticipated difficulty in intubation. 
The clinical duration of this dose of Rocuronium is, however, 50-60 minutes. 
Stoddart P.A. and Mather SJ. (1998)41 in a blinded randomized 
study, intubating conditions were compared at one minute following 
intravenous induction with propofol and either Suxamethonium 1.0 mg/kg 
or Rocuronium 0.6 mg/kg. There was no difference in the intubating 
conditions at one minute with 25 excellent/5 good in the Suxamethonium 
group and 27 excellent/3 good in the Rocuronium group. They concluded 
that Rocuronium 0.6 mg/kg gives optimal intubating conditions at one 
minute in children. 
De Rossi L.et al., (1999)11 compared the onset time of two different 
doses of Rocuronium (0.6 and 0.9 mg/kg) and Suxamethonium (1.5 mg/kg) 
preceded by 0.06 mg/kg Rocuronium at the masseter and the adductor 
pollicis muscle. Following Rocuronium and Suxamethonium, onset time is 
faster at the masseter than at the adductor pollicis muscle. 
Using a new method of monitoring neuromuscular block at the 
laryngeal muscles by surface laryngeal electromyography by Hemmerling 
T.M. et al., (2000)17 to compare the Suxamethonium with two doses of 
Rocuronium . They found that, with comparable degrees of neuromuscular 
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block, the onset time of Suxamethonium at the adductor pollicis was 
significantly shorter than for Rocuronium 0,6 mg/kg and 0.9 mg/kg. Clinical 
duration at the adductor pollicis was significantly longer for both 
Rocuronium groups than for Suxamethonium. The surface laryngeal 
electrode proved non-invasive, easy to use and reliable in measuring onset of 
the neuromuscular block at the larynx. 
 Cheng CA, Anu CS and Gin T (2002)7 conducted a study to 
detrermine whether a smaller dose of Rocuronium than previously reported 
could provide similar intubating conditions to Suxamethonium during rapid-
sequence induction of anaesthesia in children.   They concluded that 
Rocuronium 0.9 mg/kg provides similar intubating conditions to 
Suxamethonium 1.5 mg/kg during modified rapid sequence induction. 
Rocuronium 0.6 mg/kg was inadequate in children. 
During rapid-sequence induction intubation the intubating conditions 
were studied by Perry J, Lee J and Wells G (2003)34 Rocuronium and 
Suxamethonium . They concluded that Suxamethonium created superior 
intubation conditions to Rocuronium when comparing excellent intubation 
conditions. Using the less stringent outcome, clinically acceptable intubation 
conditions, the two agents were not statistically different. 
 
  
 
 
 
ANATOMY 
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ANATOMY OF NEUROMUSCULAR JUNCTION 
 
MOTOR UNITS: 
 Each motor neurons innervates many muscle fibres and the neuron 
together with the muscle fibre is motor unit. The reaction of a motor unit is 
all or none response. 
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Fig 1: Diagram of motor unit containing focally  
innervated muscle fibres. 
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NEUROMUSCULAR JUNCTION: 
 
 When the neuron reaches the muscle fibres it loses its sheath and 
divides into many branches. It ends in a small swelling embedded in muscle 
fibre to form neuromuscular junction. The nerve endings contains vesicles 
with neurotransmitters Acetylcholine. There is a gap of 20 - 50 nm between 
nerve terminal and muscle fibre called the synaptic cleft or junctional cleft. 
This cleft is filled with collagen structure named basement membrane. To this 
membrane is attached the Acetylcholinesterase. 
 
Secondary clefts are clefts formed due to folding of the muscle 
membrane at the junction. The acetyl choline receptors are formed at the 
shoulders of these clefts. There are about 106 to 107 nicotine receptors. 
 
Each receptors is a pentamer of 4 different protein subunits. Two  α 
subunits of 40,000 daltons molecular weight and single β, δ and ε subunits of 
varying daltons. The whole mol. weight of receptor is around 2,50,000 
daltons. 
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Fig 2: NMJ enlarged from motor end plate. The axon terminal contains 
mitochondria, microtubules and Acetylcholine containing vesicles. 
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POSTSYNAPTIC CHOLINERGIC RECEPTORS: 
Also called as extra junctional receptors is of 2 types: 
1.Those of foetal muscle and denervated muscle: 
       Instead of  ε subunits the receptors has γ subunit, with lifetime of 17 - 24 
hrs. 
2.Those of innervated muscle: 
        More concentrated in NMJ with lifetime of days to weeks. 
        The 2 types of these receptors react differently to agonists and 
antagonist. 
THE MUSCLE: 
        The contractile elements of a muscle cell is myofilament. The thick 
myosin and the thin actin filament attached to troponin and tropomyosin. 
        These filaments interdigitate and slide over to contract the muscle. 
Myofilament are grouped together to form myofibrils. Sarcoplasmic 
reticulum surrounding the myofibrils acts as a reservoir for calcium. The 
invaginations of sarcolemma, transverse tubules (T- tubules) comes in 
proximity to  sarcoplasmic reticulum . These tubules convey the electrical 
impulses from the surface of the muscople to the sarclasmic reticulum, 
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thereby releasing the calcium and contraction of myofilament. 
 
 
Fig 3: A schematic model showimg thr nicotinic Ach  
receptor localised in the lipid bilayer. 
Five homologous subunits (α,α,β,γ,δ of the Ach receptor may combine 
to form transmembrane aqueous pore. Both α subunits contain Ach binding 
sites. Most of the receptor is localised in the extracellular space. Each subunit 
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has four membrane spanning domains which are evident from the cross 
section of subunits. 
 
 
 
Fig 4: One of the α subunits is shown separately. The polypeptide chains 
of each subunit are postulated to cross the lipid bilayer as α helices. 
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THE MOTOR NERVE TERMINAL 
Acetycholine synthesis and storage:  
 
      
The two pools of Acetylcholine within the nerve terminal are : 
1. Releasable pool (80%) (within the vesicle) 
a. Immediately available 
b.Reserve pool 
2.Stationary or non releasable pool 
 vesicles tend to concentrate near the "Active zones" opposie crests of 
post synaptic membranes also called as "release sites". 
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THE SEPARATE POOLS OF ACETYLCHOLINE STORED  
WITHIN A NERVE TERMINAL 
 
 
ACETYLCHOLINE RELEASE: 
Acetylcholine released from the terminal occurs both spontaneously 
and by depolarisation of nerve terminal. 
SPONTANEOUS RELEASE: 
MEPPs is due to random release of quantum or packets of 
Acetylcholine, as the MEPPs are so small, many are required to generate 
Action potential. 
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DEPOLARISATION OF NERVE TERMINAL : 
Depolarisation of nerve terminal leads to the release of hundreds of 
quantum of Acetylcholine concentrated near the Release sites depending 
upon the type of the muscle. 
Following the depolarisation process, extracellular calcium passes 
through the voltage gated calcium channel . Inside the nerve terminal calcium 
binds to the proteins (Calmodulin and Calcitonin related peptide) and 
activates the enzyme necessary for Acetylcholine release. 
 The vesicular membrane consists of synaptophysin, a glycoprotein. 
Synaptotagmin in the vesicle acts as Calcium sensor. After attachment of 
calcium to synaptotagmin phosphorylation of membrane protein synapsin 
occurs so it moves to the release sites where synaptobrevin vesicle associated 
membrane protein (VAMP) attaches to the release sites leading to release of 
Acetylcholine into the synaptic cleft. 
SYNAPTIC CLEFT: 
The release of Acetylcholine into the cleft reacts with the post synaptic 
nicotinic receptors avoiding the Acetylcholinesterases enzyme , responsible 
for its hydrolysis. However eventually following its release all molecules are 
hydrolysed to inactive choline and acetate. 
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Acetylcholinesterase is a protein attached to the basement membrane. 
For each molecule of Acetylcholine released there are 10 active enzyme sites 
available. Several molecules of Acetylcholine can be hydrolysed by single 
molecule of enzyme . The arrangement allows for each molecule to act once 
with the receptor after which it is rapidly hydrolysed . Hence in normal 
physiological conditions there is no accumulation of Acetylcholine from one 
nerve stimulation to other. 
THE END PLATE: 
The resting membrane potential across the post synaptic membrane is 
90mV with inside of cell being negative (-90mV). There is excess of 
positively charged ions outside the cell. When 2 Acetylcholine molecules 
binds to the α subunits of Acetylcholine receptors conformational change 
occurs leading to flow of cations according to concentration and electrical 
gradients. There is net inward flow of sodium leading to fall in membrane 
potential . At a certain threshold of EPP (-50mV) it opens specific sodium 
channels allowing sodium to enter leading to generation of Action potential. 
Action potential draws current from the surrounding muscle fibre 
membrane and opens the voltage gated sodium channel in muscle fibre 
membrane triggering action potential in muscle fibre. Through the T tubules 
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it reaches the sarcoplasmic reticulum from which calcium is released and 
muscle contraction occurs. 
MARGIN OF SAFETY: 
The number of Acetylcholine receptors exceeds the number required to 
trigger a action potential under normal conditions . Hence around 70 - 80% of 
these Acetylcholine receptors are required to be blocked to prevent action 
potential being generated. During recovery from neuromuscular blockade 
margin of safety is important as even a normal inspiratory force, vital 
capacity and sustained head lift for 5 secs still have   70 - 80% of these 
Acetylcholine receptors blocked by the antagonists.44 
 
PHYSIOLOGY OF NEUROMUSCULAR BLOCK 
NON DEPOLARISING NEUROMUSCULAR BLOCK: 
Competitive antagonist: 
 Non Depolarising Neuromuscular Blockers are competitive antagonist 
of Acetylcholine receptors. It competes with Acetylcholine to binds with 
these receptors and prevent the action potential generation. The higher the 
concentration of this drug to the Acetylcholine, more of the receptor sites are 
occupied and neuromuscular block occurs. Similarly recovery from the block 
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occurs by decreasing the concentration of the drug or increasing the 
Acetylcholine levels by inhibiting the enzyme that hydrolyses it. However in 
this compeition between drug and Acetylcholine the bias is in favour of the 
drug. The blocker has to bind to one of the α subunit to block the channel 
whereas Acetylcholine has to bind to 2  α subunits to open the channel. 
 
In the figure above numbered  1 , at low concentrations the non depolarising 
NMB competes with Acetylcholine (ACh) for binding to postsynaptic nicotinic 
receptor sites in the skeletal muscle NMJ. 
In number 2 the nondepolarizing NMB also interfere with presynaptic 
release of ACh from motor nerve endings by mechanism poorly understood. Both 
the  Na channels and pre-synaptic nicotinic autoreceptors blockade have been 
implicated. The presynaptic nicotinic receptors have a different subunits compared 
to the muscle-type nicotinic receptors. 
          In number 3 when non depolarising NMB are given at higher concentrations 
they  produce a more intense motor blockade by blocking the pore of the nicotinic 
receptor-channel complex 
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DEPOLARISING NEUROMUSCULAR BLOCK: 
PHASE I BLOCK: 
Suxamethonium,  depolarising neuromuscular blocker acts by 
depolarising the neuromuscular end plate. Suxamethonium is hydrolysed by 
the plasma cholinesterase (pseudocholinesterase) and not by the 
cholinesterase in the cleft. So it has to diffuse from the cleft into the plasma 
for its clearance which is slower than Acetylcholine. 
There is continuous depolarisation of the end plate resulting in 
inactivation of voltage gated sodium channels preventing depolarisation of 
muscle membrane. This lasts untill Suxamethonium is diffused from the cleft 
and the end plate is repolarised. 
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In the above figure it is seen when there is continuous depolarisation of 
the end plate, the voltage gated sodium channels remains open and inactive 
preventing depolarisation of muscle membrane. This lasts untill 
Suxamethonium is diffused from the cleft and the end plate is repolarised. 
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PHASE II BLOCK: 
When Suxamethonium remains at NMJ for a prolonged time -                      
due to infusion in a normal pseudocholinesterase activity patient , or because 
of relative overdose in abnormal pseudocholinesterase activity patient, it 
causes a phase ii block. The original depolarising block changes to non 
depolarising block as the membrane potential gradually recovers to normal 
but block is persistent. 
This is described as Phase I to Phase II block. It is also called dual 
block, mixed block, desensitisation block. The term desensitisation block 
should not be used synonymously with Phase II block. 
THEORIES OF  PHASE II BLOCK: 
• Some researchers are convinced that the block is caused by 
desensitisation of receptors. 
• Some blelieved it to be by conformational changes in receptor protein. 
• Some believe the reason to be abnormal electrolyte balance over the 
end plate by prolonged depolarisation. 
• Some observed it to be channel blockade 
Management of a patient with Phase II block depends on the activity of 
30 
 
cholinesterases. In normal patients the block is antagonised by cholinesterase 
inhibitor within few minutes after discontinuing the Suxamethonium. In 
abnormal genotypics the reversal may become unpredictable leading to 
partial reversal or potentiation of the block. 
This is due to changes of quality and quantity of the 
pseudocholinesterases. Hence in abnormal genotypics Suxamethonium is 
very slowly or not hydrolysed at all in plasma, persisting in plasma. Hence 
Phase I block dominates initially followed by Phase II block, which should 
not be tried for reversal; but rather patient should be anaesthetised and 
ventilated untill full recovery from block. 
FFP and blood have been used to treat prolonged apnea. 
DESENSITISATION BLOCK: 
Thesleff studied that neuromuscular block caused by Acetylcholine, 
Suxamethonium and decamethonium applied to end plates for prolonged 
periods is due to decrease in receptor sensitivity rather than persistent 
depolarisation. The initial depolarisation occured returned to normal level and 
the receptor had turned refractory to drug effects. 
Evidence says that desensitisation is a physiological phenomenon 
occuring even when no agonists or antagonists are applied. 
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Fig 5: Different normal stages of the Acetylcholine receptors. 
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Normally receptors exists in 3 different states  
• Resting state (closed ion channel) 
• Active (open ion channel) 
• Desensitised (closed ion channel) 
 
Several factors promote desensitisation of receptors  
• High concentration of both agonists and antagonists speed up the 
process of desensitisation. 
• Drug like local anaesthetics ,volatile anaesthetics, iv anaesthetics , 
calcium channel blockers hasten the desensitisation. 
 
Mechanism by which this occurs is unknown but believed due to 
phosphorylation of one or more amino acids of  receptor proteins. 
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CHANNEL BLOCK: 
Many drugs produce block without depolarisation of end plate or 
competing with Acetylcholine to receptors, by acting at different sites of the 
receptors and preventing the passage of ions.12 
       3 different mechanisms proposed are 
• Open channel block 
• Closed channel block 
• Alteration in lipid environment of receptors 
 
In open channel block - drugs act in receptors only in open state and 
blocks the channel. Increased potentiation of receptors with use of 
anticholinesterase drug can prolong the blockade. Local anaesthetic, 
barbiturates, antibiotics and both depolarising and non depolarising muscle 
relaxants are examples of drugs causing this block. Most believe only a small 
fraction of this receptors are normally blocked in open position. when doses 
of high concentration are used the possibility of open channel block can occur 
hence difficulty in reversing these blocks can be a problem. 
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In closed channel block, the drug binds to the receptors when channels 
are in closed position. Drug like tricyclic antidepressants and quinidine 
causes this type of block. 
  Some lipid soluble drugs like inhalational agents and alcohol dissolve 
through membrane lipids changing the channel properties.21 
 
FACTORS THAT AFFECT NEUROMUSCULAR TRANSMISSION 
AND BLOCK:  
Temperature: 
 Temperature may influence events taking place in motor nerve, 
synaptic cleft, end plate, muscle. Due to a marked margin of safety in NMJ it 
is of little significance. Temperature is important in muscle contraction thus it 
is essential to maintain near normal core and peripheral body temperature. 
 If there is a drop in core temperature there is a prolonged effect of all 
the blocking agent. 
 
Electrolyte imbalance: 
Changes in the plasma potassium levels can alter the neuromuscular 
transmission and also the action of muscle relaxants. 
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According to Nernst equation. Em (mV)=61 log (k+)o/(k)i 
Em=Potential difference across the membrane 
          (k+)o - potassium concentration outside the cell 
          (k)i  - potassium concentration inside the cell 
 
 An acute decrease of k+ outside the cell with no change in the inside of 
cells will make the cell more resistant for depolarisation to Acetylcholine, 
thus a low dose of depolarising agents are enough for blocking the channel.47 
Acid base changes: 
Changes in Ph may influence  
• Membrane conduction 
• Contraction of muscles      
• Ratio of potassium both outside and inside of the cell 
• Affinity of muscle relaxant to receptors47 
 
36 
 
 
DRUG INTERACTIONS OF THE NMJ 
Drugs causing increased sensitivity to muscle relaxants, 
• Antibiotics- polymyxin B, Aminoglycosides, polypeptides, tetracyclines, 
clindamycin, lincomycin by decreasing the evoked release of 
Acetylcholine and decreased sensitivity of nicotinic receptor.47 
• Anticholinesterases- OPC, cyclophosphamide, ecothiophate eye drops 
by inhibiting the plasma cholinesterase.47 
• Inhalational agents- by dissolving in lipids of membrane influencing 
the channel protein and decreasing the Acetylcholine release. 47 
• Intravenous agents- No interaction with muscle relaxants seen.47 
• β blockers- potentiation of muscle relaxants seen but mechanism 
unknown. 47 
• Calcium channel blockers- by acting in both pre and post junctional 
receptors they potentiate the action of muscle relaxants occasionally 
reversal of blockade is difficult. 47 
• Local anaesthetics - these are fast channel blockers potentiating muscle 
relaxants action. 47 
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• Magnesium sulphate - It decreases the Acetylcholine release and 
decreases the sensitivity of post junctional membrane and excitability 
of muscle cells. 47 
 
Drugs causing decreased sensitivity to muscle relaxants 
• Antiepileptics (phenytoin, carbamazepine) 
• Azathioprine (immunosuppressants) 
• Corticosteroids and  
• Methylxanthines (Aminophylline ,theophylline) 
Mechanism of action unknown but methylxanthines inhibit the enzyme 
phosphodiesterase thereby increasing cAMP levels and possibly 
Acetylcholine. 47 
 
  
 
 
 
PHARMACOLOGY OF 
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PHARMACOLOGY OF SUXAMETHONIUM 
Suxamethonium introduced by Thesleff and Foldes et al in 1952, 
revolutionized anaesthetic practice by providing intense neuromuscular 
blockade of very rapid onset and ultra short duration, thereby greatly easing 
the maneuver of tracheal intubation. Suxamethonium is the only depolarizing 
neuromuscular blocking drug in clinical use., which is characterized by a 
rapid onset and short duration of action. A dose of 0.5 to 1 mg/kg IV 
Suxamethonium has a rapid onset (30-60 seconds) and short duration of 
action (3 to minutes). These characteristics make Suxamethonium the ideal 
drug for tracheal intubation.  
Chemistry: 
 
Two molecules of Acetylcholine linked back to back through the 
acetate methyl groups forms Suxamethonium. 
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Fig 6: Suxamethonium 50mg/ml (10ml vial) 
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Structure of Suxamethonium 
The drug is supplied in two forms, viz., the chloride and the bromide 
salts. The chloride is a white crystalline solid with a melting point of 160°C. 
It is freely soluble in water and the solution is sufficiently stable to permit the 
supply of drug as a 5% solution for clinical use. It is necessary to refrigerate 
the drug as significant degree of spontaneous hydrolysis occurs in warm 
surroundings. 
Pharmacokinetics: 
Suxamethonium is rapidly hydrolyzed in the body by 
pseudocholinesterase (plasma cholinesterase). The hydrolysis of 
Suxamethonium is a two stage process. 
Hydrolysis of Suxamethonium 
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Only a small fraction of the original IV dose of Suxamethonium 
reaches the neuromuscular junction because of the enormous capacity of 
pseudocholinesterase to hydrolyse Suxamethonium. Since there is little or no 
pseudocholinesterase at NMJ, the block of Suxamethonium is terminated by 
its diffusing away from the NMJ into the circulation. So 
pseudocholinesterase is responsible for the onset and duration of action of 
Suxamethonium.37 
Pharmacodynamics :  
Mechanism of action : 
Suxamethonium produces flaccid paralysis of skeletal muscle by 
causing persistent depolarization of post-junctional membrane. 
Suxamethonium attaches to each of the alpha sub-units of the nicotinic 
cholinergic receptors and mimics the action of Acetylcholine. Compared to 
acetylcholme the hydrolysis of Suxamethonium is slow, resulting in 
sustained depolarization of receptor ion channels. Depolarizing 
neuromuscular blockade is also known as Phase I blockade.36 
If Suxamethonium is administered in a large dose (> 2 mg/kg), 
repeated doses, or as continuous infusion, it may result in a type of blockade 
where the post junctional membranes do not respond normally to 
Acetylcholine even when the post-junctional membranes have become 
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repolarized. This type of blockade is known as phase II blockade. 
Clinical characteristics of Phase I and Phase 2 neuromuscular Blockade 
during Suxamethonium infusion 
Characteristic Phase I Transition Phase 2 
Tetanic stimulation No fade Minimal  fade Fade 
Post-tetanic facilitation None Slight Yes 
TOF No Mod. fade Marked fade 
TOF ratio >0.7 0.4-0.7 <0.4 
Edrophonium bromide Augments Little effect Antagonizes 
Recovery Rapid Rapid to slow Increasingly 
prolonged 
Does requirements 
(mg/kg) 
2-3 4-5 >6 
Tachyphylaxis No Yes Yes 
 
Dibucaine number and pseudocholinesterase Activity: 
A Suxamethonium blockade is prolonged in patients with abnormal 
genetic variant of pseudocholinesterase. The variant was found by Kalow 
and Genest. Dibucaine inhibits normal pseudocholinesterase greatly than the 
abnormal variant which led to the development of Dibucaine number. Under 
standardized test conditions, dibucaine, a local anaesthetic inhibits the 
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normal enzyme about 80 percent and the abnormal enzyme about 20 
percent. 
Although the dibucaine number gives genetic makeup of an individual 
with respect to pseudocholinesterase, it does not measure the quantity of 
enzyme in the plasma, nor the quality of the enzyme in hydrolyzing a 
substrate such as Suxamethonium . Both the factors are accounted for in 
measurements of pseudocholinesterate activity.  
Cardiovascular effects : 
  The drug stimulates the cholinergic receptors ; nicotinic receptors on 
both sympathetic and parasympathetic ganglia and muscarinic receptors in 
SA node of the heart. In low doses, both negative inotropic and chronotropic 
effect may occur. These can be decreased by prior administration of atropine. 
With large doses of Suxamethonium, these effects may become positive. One 
prominent clinical manifestation  is the development of cardiac arrhythmias, 
manifested as sinus bradycardia, junctional rhythms, and ventricular 
arrhythmias, ranging from unifocal premature ventricular contraction to 
ventricular fibrillation in certain circumstances such as burns.  
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Sinus Bradycardia: 
The mechanism involved in sinus bradycardia is stimulation of cardiac 
muscarinic receptors in the SA node, individuals with high sympathetic tone, 
such as children who have not received atropine. Sinus bradycardia noted in 
adults appear more commonly if second dose is given 5 minutes after the 
first. The bradycardia is prevented by thiopental, atropine, ganglion-blocking 
drugs, and nondepolarizing muscle relaxants. This effect is due to increased 
muscarinic stimulation, and ganglionic stimulation. The high incidence of 
bradycardia after a second dose of succinylcholine suggests that the 
hydrolysis products of Suxamethonium may sensitize the heart to a 
subsequent dose.  
Nodal (Junctional) Rhythms: 
Junctional rhythms are bradycardia slower than the sinus rate measured 
before the administration of Suxamethonium and intubation of the trachea. 
The mechanism involves greater stimulation of muscarinic receptors in the 
sinus node, suppreses the sinus mechanism and allowing the emergence of 
the atrioventricular node as the pacemaker. The incidence is greater after 
second dose of Suxamethonium but is prevented by prior administration of d-
tubocuraine (dTc).  
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Ventricular Arrhythmias: 
Drugs like tricyclic antidepressants, digitalis, exogenous 
catecholamines,  monoamine oxidase inhibitors, and anesthetic drugs such as 
halothane and cyclopropane  lowers the ventricular threshold for ectopic 
activity or increase the arrhythmogenic effect of catecholamines. Ventricular 
escape beats occur as a result of severe sinus and atrioventricular nodal 
slowing secondary to Suxamethonium administration. The incidence of 
ventricular arrhythmias is further increased by the release of potassium from 
skeletal muscle as a consequence of the depolarizing action of the drug. 
Suxamethonium and hyperkalemia: 
Studies have shown that in patients with certain disease and 
conditions, an exaggerated release of potassium occurs in response to 
Suxamethonium. Such conditions include bums, nerve damage or 
neuromuscular disease, closed head injury, intraabdominal infection and 
renal failure.37 
Rhabdomyolysis and hyperkalemia may occur when Suxamethonium 
is administered to children with undiagnosed myopathy.42 For these reasons 
some anaesthesiologists avoid the use of Suxamethonium in paediatric 
patients and prefer nondepolarizing neuromuscular blocking drugs. 
Proliferation of extrajunctional cholinergic receptors providing more sites for 
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potassium to leak outward from cells during depolarization is the presumed 
explanation for hyperkalemia that follows the administration of 
Suxamethonium to patients with denervation injury.37 
In burns patients, the hyperkalaemic response that follows 
Suamethonium administration is markedly exaggerated. The mechanism of 
this exaggerated response to Suxamethonium seems to be similar to that in 
vicitims of denervation inujuries.45 
Patient with chronic renal failure often have elevated baseline plasma 
potassium. More studies have shown that renal failure patients are not 
susceptible to an increased response to Suxamethonium than those with 
normal renal function. 
Suxamethonium and intraocular pressure : 
 The increase in intraocular pressure is known to be caused by 
contraction of tonic myofibrils or transient dilatation of choroidal blood 
vessels.  The intravenous administration of Suxamethonium is typically 
followed by an increase in intraocular pressure (by 5-10 mm Hg). The onset 
is within 1 minute after injection, peaks around 2-4 minutes and subsides in 6 
minutes.  The patients undergoing ophthalmic procedures are likely to be at 
risk from increased introcular pressure.37 
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Suxamethonium and intragastric pressure: 
Suxamethonium produces inconsistent increase in intragastric 
pressure. When intragastric pressure increases it seems to be related to the 
intensity of skeletal muscle fasciculation induced by Suxamethonium. 
Pretreatment with either a nondepolarizing muscle relaxant or lignocaine 
decrease both the fasciculation and the increased gastric pressure effectively. 
A far less increase in intragastric pressure is observed in infants and children. 
This may be related to the minimal or absent fasciculations from 
Suxamethonium in these age groups. 37 
Suxamethonium and intracranial pressure: 
Increase in intracranial pressure after administration of 
Suxamethonium to patients with intra cranial tumours or head trauma have 
not been a consistent observation. Patients in whom such an increase in 
intracranial pressure is not acceptable, a nondepolarizing muscle relaxant 
should be substituted for Suxamethonium, if at all possible. 37 
Suxamethonium and myalgia: 
Postoperative skeletal muscle myalgia can occur after administration 
of Suxamethonium. It is said that the muscle pain is due to the damage 
produced in the skeletal muscle by unsynchronized contraction of muscle 
fibres just before paralysis occurs. Pretreatment with a minimal dose of a 
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nondepolarizing muscle relaxant prevents Suxamethonium induced muscle 
fasciculation and reduces the incidence and severity of post operative muscle 
pain. 37 
Masseter Spasm : 
Suxamethonium causes masseter spasm, especially in children. In all 
likelihood, this is an increased contractile response at the NMJ.37 
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PHARMACOLOGY OF ROCURONIUM 
Rocuronium is classified under non depolarising muscle relaxants 
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STRUCTURE 
 
 
 
 
 
 
Fig 7: Rocuronium vial 100mg/10ml (10ml vial). 
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Structure of Rocuronium 
Rocuronium is a newer amino steroid based neuromuscular blocking 
agent with short onset of action and intermediate duration of action. 
Recuronium is a 2-morpholino, 3-desacetyl, 16-N-allyl pyrolidino derivative 
of vecuronium. It differs from vecuronium at third position on the steroid 
nucleus and the absence of the Acetylcholine like fragment. The methyl 
group attached to the quaternary nitrogen of vecuronium is replaced by an 
allyl group and the absence of Acetylcholine like fragment in the A-ring may 
be partly responsible for the decrease in potency seen with Rocuronium. 
Rocuronium possess tertiary nitrogen at the ring A end of the molecule. It is 
the replacing of acetate group by a hydroxy group attached to the A-ring, 
made it possible to present Rocuronium as a stable solution. 
PHARMACOKINETICS 
Rocuronium is taken up by a carrier mediated active transport system 
into the liver. Rocuronium is excreted unchanged in the bile. Desacetylation 
of Rocuronium does not occur and the putative metabolities 17-
desacetylRocuronium have not been detected in significant quantities. Renal 
excretion of Rocuronium may be > 30% in 24 hours. In patients with renal 
failure, Rocuronium may produce longer duration of action.10 In patients with 
liver disease there is increase in the volume of distribution and may result in 
prolonged duration of action.  
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PHARMACODYNAMICS  
Mechanism of Action: 
Rocuronium being an aminosteroid based neuromuscular blocking 
agents, has a post junctional effect and high degree of selectivity for receptors 
at the neuromuscular junctions. Muscle paralysis is produced by competitive 
antagonism of nicotinic cholinergic receptor of skeletal muscle. Its potency is 
about 10 - 15% of vecuronium in man.32  Rocuronium antagonizes 
Acetylcholine receptor, therefore, it is likely that it competes with 
Acetylcholine at its binding site. The tetanic fade phenomenon is observed 
with Rocuronium indicating activity not only at post synaptic but also at pre 
synaptic nicotinic receptors. Activity is terminated by gradual dissociation 
from the receptor shifting the agonist/antagonist equilibrium in favour of 
Acetylcholine.  
Dosage, Onset and Duration of action : 
 Rocuronium has a rapid onset of neuromuscular block, presumably due 
to the relatively low potency of Rocuronium. The intubating dose of 
Rocuronium is 0.6 mg/kg. 
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Dosage and Clinical duration of Rocuronium 
 Dosage (mg/kg) 
Clinical 
duration 
(minutes) 
ED95 0.3-0.4  
Intubation at t=60-90 seconds 0.6-1.0 35-75 
Relaxation (N20/ 02) 0.3-0.4 30-40 
Relaxation (vapour) 0.2-0.3 30-40 
Maintenance 0.1-0.15 15-25 
Infusion 8-12 u/kg-1/min-1  
 
Onset of action of Rocuronium is shorter when compared with other 
nondepolarizing muscle relaxants.6 When the dose of Rocuronium is 
increased, onset of action decreases further. 
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Onset and Duration of action of Rocuronium 
 Rocuroniu
m 0.6 
mg/kg 
Rocuroniu
m 0.9 
mg/kg 
Rocuronium 
1.2 mg/kg 
Onset 
Mean 89 75 55 
SD 33 28 14 
Range 48-156 48-144 36-84 
Duration (minutes) 
Mean 37 53 73 
SD 15 21 32 
Range 23-75 25-88 38450 
 
When the dose of Rocuronium is increased the onset of action is 
definitely decreased but the duration of action is increased.  
Rocuronium can be used for continuous infusion. The infusion rate will 
depend on the anaesthetic technique and age of the patient. It can be used at 
a rate of 0.3 to 0.6 mg/kg/hr (5-10 ug/kg/min).38  
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Recovery: 
For an intubating dose of Rocuronium 0.6 mg/kg, the time required 
for the recovery of twitch height from 25% to 75% is approximately 14 
minutes. 
 
Recovery index of three doses of Rocuronium 
 Rocuronium 
0.6 mg/kg 
Rocuronium 
0.9 mg/kg 
Rocuronium 
1.2 mg/kg 
Recovery Index 
Mean 14 22 24 
SD 8 14 11 
Range 6-27 8-29 11-43 
 
Rocuronium and cardiovascular effects 
Rocuronium is typically devoid of cardiovascular effects. Circulatory 
effects or the release of histamine do not occur after the rapid IV 
administration of even large doses of Rocuronium. The structural feature 
responsible for this difference is the absence of Acetylcholine-like character 
of A-ring substitution, which decreases the action on cardiac muscaranic 
receptors. 
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Rocuronium, however, may produce a slight vagolytic action.  This 
feature of Rocuronium may be useful in patients undergoing surgical 
procedures that may be associated with vagal stimulation.  
Rocuronium and cardio pulmonary bypass : 
Under hypothermic (post-bypass conditions) the Rocuronium 
requirements are reduced39.   Factors, which may play a role in the changed 
concentration response relationship and changed biodisposition during 
hypothermia are: 
• An increased sensitivity of NMJ related to a decreased acetylcholine 
mobilization. 
• A diminished muscle contractility due to changed mechanical 
properties and / or electrolyte shifts (Mg2+ and Ca2+) resulting from 
the application of cardio pulmonary bypass. 
• Increased unbound relaxant fraction due to haemodilution, despite a 
decreased total Rocuronium concentration. 
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Rocuronium and age: 
The potency of Rocuronium is significantly greater in infants than in 
children or adults.28 Infants have 20-30% smaller ED50 and ED95 values 
than children or adults, while differences between children and adults were 
minimal. This pattern of age dependency is similar to that with other non-
depolarizing muscle relaxants, which show that dose, requirement is smallest 
in infants. If this difference in potency is translated into clinical practice it 
means that if children or adults are given a dose of 600 ug/kg, an equipotent 
does in infants would be 450 ug/kg. If no adjustment in dose is made, there 
would be a much longer duration of effect in infants than children or adults.  
Rocuronium and caesarean section : 
Rocuronium had no untoward effects on the neonates, evaluated by 1 
and 5 minutes scores, when Rocuronium 0.6 mg/kg" was used in 40 elective 
caesarean section patients full term, without fetal distress.2  
Rocuronium and hepatic cirrhosis: 
The clearance of Rocuronium may be reduced in the presence of 
hepatic cirrhosis and thus it is advisable to reduce the dose of drug used in 
these patients.20 
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Rocuronium and renal failure: 
There is no significant difference in the onset and duration of action of 
Rocuronium between patients with and without renal failure.  Patients with 
renal failure showed a significantly lower clearance and an increased mean 
residence time.9 
Rocuronium Bromide in the ICU: 
Muscle relaxation with Rocuronium should be maintained by 
continuous infusion, whenever its use is indicated in the ICU. An average of 
45mg Rocuronium per hour provide, optimal conditions for ventilation and 
nursing maneuvers. Monitoring of neuromuscular function is strongly 
advised because of the substantial inter-individual differences in the dose 
required by ICU patients. With continuous monitoring of neuromuscular 
function, no residual paralysis or muscle weakness is observed.22 
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METHODOLOGY 
This study was conducted in Institute of Anaesthesiology and Critical 
care at Madras medical college, Chennai during the period 2014 – 15. Ethical 
committee clearance was obtained from the institution for this study purpose 
 
INCLUSION CRITERIA: 
• Age            :  18 – 60 years 
• Weight      :  BMI < 30 Kg/m2 
• ASA            :  I & II 
• Surgery     :  Elective 
• Mallampatti  scores  :  I & II 
• Who have given valid informed consent. 
 
EXCLUSION CRITERIA: 
• Not satisfying inclusion criteria. 
• Patients posted for emergency surgery 
• Patients with difficult airway 
• Lack of written informed consent 
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• Pregnant female 
• Neuromuscular disorders 
• Obese individual 
• Allergy to Suxamethonium or Rocuronium 
 
Materials: 
• Mac Intosh laryngoscope 
• Single use PVC endotracheal tubes with size 7.0 & 8.0mm ID 
• Drugs – Suxamethonium and Rocuronium 
• Monitors – ECG,NIBP,SPO2. 
 
Methods: 
The study involved 100 patients who were randomly divided into main 
groups of 50 patients each with the first group being the Suxamethonium and 
the second group being the Rocuronium assessed for intubating conditions 
after administration of corresponding drug. 
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All patients were subjected to a detailed pre-anaesthetic evaluation and 
the presence of significant systemic diseases and difficult airways were ruled 
out. Informed consent was taken and the procedure was explained to them. 
All patients were given 0.5mg of Alprazolam and 150mg of Ranitidine orally 
on the previous night of surgery. On the morning of surgery an intravenous 
line was secured with appropriate size.  
Patient monitors: 
Monitors included non - invasive blood pressure monitor, ECG, 
pulseoximeter.  
 
Induction: 
All patients were preOxygenated with 100% Oxygen for 3 – 5 minutes. 
Pre induction heart rate and blood pressure was measured. Patients were 
induced with Thiopentone 5 mg/kg iv. Patients were ventilated with 100% 
Oxygen for 60 seconds. Intubating conditions were assessed after 
administration of neuromuscular blocker in 60 seconds. The intubating 
conditions were assessed according to the scoring system by Kreig et al 
(1980) modified by Cooper et al (1992). Parameters taken into consideration 
were jaw relaxation, vocal cords movement and gross response to intubation. 
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Intubating conditions scoring system 
Score JAW 
RELAXATION 
VOCAL CORDS 
MOVEMENT 
RESPONSE TO 
INTUBATION 
0 Poor(impossible) Closed Severe coughing or 
bucking 
1 Minimal(difficult) Closing Mild coughing 
2 Moderate(fair) Moving Slight diaphragmatic 
movement 
3 Good(easy) Open None 
 
The scores were added up and grouped as 
8 – 9 = Excellent                  6 – 7 = Good 
3 – 5 = Fair                        0 – 2 = Poor 
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After intubation the cuff of the endotracheal tube was inflated and the 
tube was connected to the circuit and controlled ventilation was started with 
Nitrous oxide, Oxygen and volatile anaesthetic. The intubating conditions 
assessed in 60 seconds was noted and the results were analysed and tabulated. 
The Fisher Exact test and t-test were used in statistical analysis of data. At the 
end of surgery the block was reversed with 0.05 mg/kg of neostigmine and 
0.04mg/kg of glycopyrrolate. The patients were extubated after thorough oral 
suctioning. Any untoward effects were recorded. 
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RESULTS 
This study was conducted  during the period 2014 – 15 and involved 
100 patients undergoing elective surgery under GA. They were randomly 
divided into two main groups with Group 1 receiving Suxamethonium and 
Group 2 receiving Rocuronium and the intubating conditions were assessed 
in 60 seconds according to the system proposed by Cooper et al and were 
classified as excellent, good, fair and poor. 
 
Table 1: group  distribution with t- test below 
Group Statistics
50 30.34 12.245 1.732
50 33.08 12.127 1.715
Group
GROUP - I 
Suxamethonium ( 1.5
mg/kg)
GROUP - II Rocuronium
(1.0mg/kg)
Age  ( In Years )
N Mean Std. Deviation
Std. Error
Mean
 
 
Independent Samples Test
.283 .596 -1.124 98 .264 -2.740 2.437 -7.577 2.097
-1.124 97.991 .264 -2.740 2.437 -7.577 2.097
Equal variances
assumed
Equal variances
not assumed
Age  ( In Years )
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
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Table 2: Age distribution in each group 
Age  ( In Years ) * Group Crosstabulation
31 23 54
62.0% 46.0% 54.0%
10 13 23
20.0% 26.0% 23.0%
4 10 14
8.0% 20.0% 14.0%
5 4 9
10.0% 8.0% 9.0%
50 50 100
100.0% 100.0% 100.0%
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
< 30 Years
31 - 40 Years
41 - 50 Years
51 - 60  Years
Age  ( In
Years )
Total
GROUP - I 
Suxameth
onium ( 1.
5 mg/kg)
GROUP - II
Rocuronium
(1.0mg/kg)
Group
Total
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                Table 3 : Weight distribution in each group with t- test below 
Group Statistics
50 54.14 9.493 1.343
50 61.98 9.027 1.277
Group
GROUP - I 
Suxamethonium ( 1.5
mg/kg)
GROUP - II Rocuronium
(1.0mg/kg)
Body Wt Kg
N Mean Std. Deviation
Std. Error
Mean
 
Independent Samples Test
.071 .791 -4.232 98 .000 -7.840 1.853 -11.516 -4.164
-4.232 97.753 .000 -7.840 1.853 -11.517 -4.163
Equal variances
assumed
Equal variances
not assumed
Body Wt Kg
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
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Table 4 : Sex distribution in each group with t- test below 
Sex * Group Crosstabulation
28 28 56
56.0% 56.0% 56.0%
22 22 44
44.0% 44.0% 44.0%
50 50 100
100.0% 100.0% 100.0%
Count
% within Group
Count
% within Group
Count
% within Group
Male
Female
Sex
Total
GROUP - I 
Suxameth
onium ( 1.
5 mg/kg)
GROUP - II
Rocuronium
(1.0mg/kg)
Group
Total
 
 
Chi-Square Tests
.000b 1 1.000
.000 1 1.000
.000 1 1.000
1.000 .580
.000 1 1.000
100
Pearson Chi-Square
Continuity Correction a
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count less than 5. The minimum expected count is 22.
00.
b. 
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Table 5 : Intubating conditions distribution in each group  
with t-test below 
Group Statistics
50 8.36 .749 .106
50 7.54 .994 .141
50 2.70 .463 .065
50 2.52 .544 .077
50 2.68 .471 .067
50 2.34 .557 .079
50 2.98 .141 .020
50 2.70 .463 .065
Group
GROUP - I 
Suxamethonium ( 1.5
mg/kg)
GROUP - II Rocuronium
(1.0mg/kg)
GROUP - I 
Suxamethonium ( 1.5
mg/kg)
GROUP - II Rocuronium
(1.0mg/kg)
GROUP - I 
Suxamethonium ( 1.5
mg/kg)
GROUP - II Rocuronium
(1.0mg/kg)
GROUP - I 
Suxamethonium ( 1.5
mg/kg)
GROUP - II Rocuronium
(1.0mg/kg)
Cooper Scoring System
Jaw Relaxation
Vocal Cords
Response to Intubation
N Mean Std. Deviation
Std. Error
Mean
 
Independent Samples Test
1.971 .163 4.658 98 .000 .820 .176 .471 1.169
4.658 91.100 .000 .820 .176 .470 1.170
8.712 .004 1.783 98 .078 .180 .101 -.020 .380
1.783 95.574 .078 .180 .101 -.020 .380
2.667 .106 3.294 98 .001 .340 .103 .135 .545
3.294 95.363 .001 .340 .103 .135 .545
137.533 .000 4.090 98 .000 .280 .068 .144 .416
4.090 58.068 .000 .280 .068 .143 .417
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Cooper Scoring System
Jaw Relaxation
Vocal Cords
Response to Intubation
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
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  In both the groups with respect to age, body weight and sex 
distribution it is statistically not significant 
The intubating conditions assessed at 60 seconds following the 
administration of corresponding neuromuscular blockers were observed to be 
excellent in 42 patients(84%) in group I (Suxamethonium) while they were 
excellent in 26 patients(52%) in group II (Rocuronium) .The intubating 
conditions were good in 8 patients(16%) in group I (Suxamethonium) while 
they were good in 21 patients (42%) in group II (Rocuronium). The 
intubating conditions was observed to be fair in 3 patients (6%) in group II 
(Rocuronium). In all the patients (100%) in Group I (Suxamethonium) it was 
observed that the intubating conditions was better with dense neuromuscular 
blockade whereas it was observed in 47 patients (94%) in group II 
(Rocuronium) the intubating conditions were good to excellent and was 
acceptable. The result was significant with a p value of < 0.01. 
According to the cooper scoring system the scores of vocal cord 
movement in group I (Suxamethonium) was 2.68(mean) ±0.471 and in group 
II (Rocuronium) was 2.34±0.557 , the scores of response to intubation in 
group I (Suxamethonium) was 2.98±0.141 and in group II (Rocuronium) 
was2.70±0.463 with better intubating conditions in group I receiving 
Suxamethonium than Rocuronium.The results was significant with p value of 
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<0.05. whereas the scores of jaw relaxation in group I 
patients(Suxamethonium) was 2.70(mean)±0.463 and group II patients 
(Rocuronium) was 2.52±0.544 with better jaw relaxation.The results was not 
significant as p value >0.05. In overall scoring the results was significant 
with better intubating conditions in patients receiving Suxamethonium. 
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Table 7: HEART  RATE VARIATION 
Time of monitoring I II 
Resting 83.4 ±9.9 84.2±12.9 
After induction 95.4±12.6 97.6±14.4 
After intubation at 1 
minute 
100±10.2 103.4±12.4 
At 2 minutes 98±10.1 100.2±11.6 
At 5 minutes 92.6±11.4 94.6±12.2 
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Table 8: MEAN ARTERIAL PRESSURE 
Time of monitoring  I II 
Resting 91.8±7.0 93.3±6.7 
After induction 92.6±8.4 93.6±5.9 
After intubation at 1 
minute 
98.4±7.2 106.4±8.2 
At 2 minutes 95.4±8.5 98.2±6.3 
At 5 minutes 94.6±10.2 96.4±9.2 
 
The above tables shows mean heart rate and mean arterial pressure 
variation in two groups. It shows that both are increased in two groups after 
induction was maximum at 1 minute afterwards it gradually returns to 
normal. 
 
 
 
  
 
 
 
DISCUSSION 
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DISCUSSION 
  In patients undergoing elective surgeries under GA the airway of 
anaesthetised patient needs to be secured at the earliest for which we need a 
muscle relaxant of rapid onset, which also prevents the aspiration of gastric 
contents in patients who have full stomach, delayed gastric emptying time, 
impaired function of lower oesophageal sphincter. Suxmethonium was the 
often used drug till now for rapid onset of intubating conditions. Still the side 
effects it may produce may range from post operative myalgia to life 
threatening complications like dysrhythmias, hyperkalemia ,malignant 
hyperthermia. 
Rocuronium is a non depolarising muscle relaxant that first came into 
use in 1990s . It showed acceptable faster onset of action compared to other 
non depolarising muscle relaxant. There are studies showing different dosage 
regimens of Rocuronium producing acceptable intubating conditions. Certain 
studies shows that it can be used as an alternative to Suxamethonium in rapid 
sequence induction.27, 34 
 Previous studies showed that intubating conditions at 60 seconds were 
generally good with a dose of 0.6 mg/kg of Rocuronium.10,35,46 Use of higher 
doses of Rocuronium by workers have been observed to increase the onset of 
intubating conditions during rapid sequence induction with increased duration 
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of action.40,27,34 
In our study the intubating conditions following administration of 1 
mg/kg of Rocuronium was compared with Suxamethonium 1.5 mg/kg in 60 
seconds in different patients undergoing elective surgeries. 
The intubating conditions assessed at 60 seconds following the 
administration of corresponding neuromuscular blockers were observed to be 
excellent in 42 patients(84%) in group I (Suxamethonium) while they were 
excellent in 26 patients(52%) in group II (Rocuronium) .The intubating 
conditions were good in 8 patients(16%) in group I (Suxamethonium) while 
they were good in 21 patients (42%) in group II (Rocuronium). The 
intubating conditions was observed to be fair in 3 patients (6%) in group II 
(Rocuronium). 
 In our study the hemodynamic response were also recorded . the results 
shown in table 7 & 8 was comparable and statistically not significant in both 
the groups. 
 Our findings were comparable with to the study conducted by Cooper 
et al, (1992).8 Rocuronium used at the dose of 0.6mg/kg produced excellent 
intubating conditions in 60% of patients compared to 95% in patients 
received Suxamethonium. In our study it was found when Rocuronium used 
at the dose of 1mg/kg it produced excellent intubating condition in 52% of 
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patients compared to 84% in patients received Suxamethonium. 
 Acceptable intubating conditions in Cooper 's study were 95% in 
Rocuronium group compared to 100% in Suxamethonium in 60 seconds,  in 
our study the intubating conditions were acceptable in around 94% of the 
patients compared to 100% patients received Suxamethonium 
Our findings were also similar to findings of Huzinga et al (1992)18 
who reported the intubating conditions were acceptable  in 100% of patients 
but  the dosage Rocuronium used was 0.6 mg/kg at 60 seconds after 
administration 
Puhringer et al (1995)35 reported 100% acceptable intubating 
conditions with both Suxamethonium and Rocuronium in 100% of the 
patients. 
Larsen et al (2005) reported comparable acceptable intubating 
conitions in both Suxamethonium(1.5mg/kg) and Rocuronium(1mg/kg) for 
rapid sequence intubation in trauma emergency cases. 
It is seen that Rocuronium can be used to provide acceptable intubating 
conditions near equivalent to Suxamethonium making it an alternative. 
Rocuronium has the disadvantage of having intermediate duration of action, 
with its standard intubating dosage regimens. Hence it is not recommended 
for patients with anticipated difficult intubation. A failed intubation in 
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patients given Rocuronium can prove dangerous because of its intermediate 
duration of action. Suxamethonium with its rapid termination of action is a 
safer agent with anticipated difficult intubation. 
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CONCLUSION 
Suxamethonium provides ideal intubating conditions very rapidly than 
Rocuronium, but Rocuronium also provides intubating conditions that are 
acceptable for earlier establishment of airway with minimal injury at 60 
seconds at a dose of 1mg/kg near equivalent to Suxamethonium. As 
Suxamethonium has numerous side effects, Rocuronium can be chosen as an 
alternative to it even in rapid sequence intubation in emergency cases, 
provided the airway is properly assessed and no anticipated difficult 
intubation is present. 
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SUMMARY 
 
This prospective controlled study was conducted with Suxamethonium 
and Rocuronium in 100 patients undergoing elective surgeries under GA.  
Each of the drug was given to a group of 50 patients and the intubating 
conditions was assessed in 60 seconds. The results obtained showed that 
acceptable (good to excellent) intubating conditions were present in 94% of 
the patients in 60 seconds after administration. While all (100%)  patients had 
acceptable intubating conditions in 60 seconds after administration of 
Suxamethonium.  
The results showed that Rocuronium had equivalent amount of jaw 
relaxation in patients compared with Suxamethonium, while the vocal cords 
movement and response to intubation was better with Suxamethonium when 
compared with Rocuronium. 
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ANNEXURES 
PROFORMA 
DATE:                                 ROLL NO:                     AIRWAY DEVICE: 
NAME:  
AGE:                    SEX:                       IP NO: 
DIAGNOSIS: 
SURGICAL PROCEDURE DONE: 
Ht:                                                                 CVS:                                 HB: 
Wt:                                                                   RS: 
AIRWAY:MMC -                                                         IID      -                                         DENTITION - 
PRE OP ASSESSMENT: 
HISTORY:    Any Co-morbid illness 
                     H/O Documented Difficult Airway 
                     H/O previous surgeries 
                     H/O any drug allergy 
MEASURES OF STUDY OUTCOME: 
INTRAOPERATIVE HAEMODYNAMICS: 
                                                         HR               SBP          DBP         MAP       SPO2 
PRE OP: 
INDUCTION: 
MR WITH SUXAMETHONIUM/ROCURONIUM 
GRADING OF INTUBATING CONDITION         
Score JAW RELAXATION VOCAL CORDS 
MOVEMENT 
RESPONSE TO 
INTUBATION 
0 Poor(impossible) Closed Severe coughing or bucking 
1 Minimal(difficult) Closing Mild coughing 
2 Moderate(fair) Moving Slight diaphragmatic movement 
3 Good(easy) Open None 
 
EXTUBATION 
SIDE EFFECTS 
  
  
  
 
 
 
 
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
 
 
  
  
 
 
INFORMATION TO PARTICIPANTS 
Investigator :  
Name of the Participant: 
Title: “A Prospective,   randomized controlled study to compare the 
intubating conditions achieved with suxamethonium and rocuronium bromide ”. 
You are invited to take part in this research study.We have got approval from the 
IEC. Your are asked to participate because you satisfy the eligibility criteria.We want to 
compare the onset time and intubating condition achieved with suxamethonium and 
rocuronium bromide. 
 
What is the Purpose of the Research: 
This study is done to compare the intubating conditions achieved with 
suxamethonium and rocuronium bromide.  
 
The Study Design: 
All the patients in the study will be divided into two groups. 
Group 1-Muscle relaxant with suxamethonium(1.5mg/kg). 
Group 2-Muscle relaxant with rocuronium  bromide(1mg/kg) 
Benefits 
          The use of muscle relaxants will facilitate in easier intubation and minimizing the 
risk of airway injury and maintaining haemodynamic stability. 
Discomforts and Risks 
           The use of muscle relaxants can cause post operative myalgia, rise in serum 
potassium, bradycardia, rise in intra ocular and intra cranial pressure, prolonged recovery 
and malignant hyperthermia. 
This intervention has been shown to be well tolerated as shown by previous 
studies.  And if you do not want to participate you will have alternative of setting the 
standard treatment and your safety is our prime concern. 
Time :                                                                     
Date : 
Place : 
Signature / Thumb Impression of Patient 
Patient Name: 
 
Signature of the Investigator : ____________________________ 
Name of the Investigator : ____________________________ 
 
 
 
 
  
PATIENT CONSENT FORM 
Study title        :          “A Prospective,   randomized controlled study to compare the  
intubating conditions achieved with suxamethonium and 
rocuronium bromide.” 
 
Study center:       
INSTITUTE OF ANAESTHESIOLOGY AND CRITICAL CARE, 
             RAJIV  GANDHI GOVT. GENERAL HOSPITAL,  
             MADRAS MEDICAL COLLEGE, 
CHENNAI 3. 
Participant name :                                                Age:                         Sex:                                
I.P.No: 
 
 
      I confirm that I have understood the purpose of procedure for the above study . I have the 
opportunity to ask the question and all my questions and doubts have been answered to my 
satisfaction. 
 
I have been explained about the pitfall in the procedure.  I have been explained about the 
safety, advantage and disadvantage of the technique. 
 
            I understand that my participation in the study is voluntary and that I am free to withdraw 
at anytime without giving any reason. 
 
            I understand that investigator ,regulatory authorities and the ethics committee will not need 
my permission to look at my health records both in respect to current study and any further 
research that may be conducted in relation to it, even if I withdraw from the study . I understand 
that my identity will not be revealed in any information released to third parties or published , 
unless as required under the law . I agree not to restrict the use of any data or results that arise from 
the study . 
 
Time:          
Date:                                                                              Signature / thumb impression of patient  
Place:                                                                             Patient name: 
Signature of the investigator: 
Name of the investigator: 
  
  
 
KEY TO MASTER CHART 
 
S.No  - Serial number 
IP.No.  - In patient no 
M   - Male 
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